CD274 and neoplasm: Collectively, these findings support a rationale for combination MAPK signalling and PD-L1 blockade to boost anti-tumour immunity as MAPK-induced upregulation of novel ICs such as TIM-3, LAG-3 and A2aR might represent mechanisms of immune escape or acquired resistance to PD-L1 ICB.